| Literature DB >> 30126384 |
Abstract
BACKGROUND: To compare clinical characteristics and antibiotic susceptibilities in patients with Pseudomonas aeruginosa (PA) and P. putida (PP) keratitis at a tertiary referral center in South Korea.Entities:
Keywords: Antimicrobial susceptibility; Contact lenses; Pseudomonas aeruginosa; Pseudomonas putida; Ulcerative keratitis
Mesh:
Substances:
Year: 2018 PMID: 30126384 PMCID: PMC6102849 DOI: 10.1186/s12886-018-0882-3
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Epidemiologic characteristics and predisposing factors of Pseudomonas aeruginosa and P. putida keratitis
| Characteristics |
|
| |
|---|---|---|---|
| Male sex | 16 (48.5) | 7 (43.8) | 0.755 |
| Age, mean ± SD, years | 47.0 ± 24.4 | 59.3 ± 18.9 | 0.060† |
| Age subgroup | |||
| 0–19 | 2 (6.1) | 1 (6.3) | 1.000* |
| 20–39 | 14 (42.4) | 1 (6.3) | 0.018* |
| 40–59 | 4 (12.1) | 6 (37.5) | 0.060* |
| ≥ 60 | 13 (39.4) | 8 (50.0) | 0.482 |
| Symptom duration‡ | |||
| mean ± SD, days | 4.3 ± 3.9 | 9.5 ± 7.8 | 0.022† |
| > 5 days | 8 (24.2) | 11 (68.8) | 0.003 |
| Duration of hospitalization§, | |||
| mean ± SD, days | 10.4 ± 6.4 | 8.6 ± 4.9 | 0.325† |
| Seasonal distribution | |||
| Spring (Mar-May) | 7 (21.2) | 2 (12.5) | 0.698* |
| Summer (Jun-Aug) | 6 (18.2) | 6 (37.5) | 0.169* |
| Autumn (Sep-Nov) | 15 (45.5) | 3 (18.8) | 0.069 |
| Winter (Dec-Feb) | 5 (15.2) | 5 (31.3) | 0.261* |
| Predisposing factors | |||
| Corneal trauma | 9 (27.3) | 10 (62.5) | 0.018 |
| Contact-lens wear | 12 (36.4) | 0 (0.0) | 0.005* |
| Previous OSD# | 7 (21.2) | 6 (37.5) | 0.304* |
| Previous ocular surgery¶ | 5 (15.2) | 3 (18.8) | 1.000* |
| Previous topical antibiotics use | 12 (36.4) | 8 (50.0) | 0.362 |
| Previous topical steroid use | 5 (15.2) | 0 (0.0) | 0.158* |
| Systemic disease** | 10 (30.3) | 7 (43.8) | 0.354 |
| No apparent cause | 8 (24.2) | 4 (25.0) | 1.000* |
SD standard deviation, OSD ocular surface disease
Values indicate numbers (proportion) unless otherwise noted
*The p-value was calculated using Fisher’s exact test
†The p-value was calculated using independent t-test
‡Interval from the onset of symptoms to the time of initial presentation
§The period from admission to discharge
#P. aeruginosa group included necrotizing scleritis (two cases), exposure keratopathy (two cases), neurotrophic keratopathy (one case), bullous keratopathy (one case), and previous corneal ulcer (one case); P. putida group included exposure keratopathy (two cases), pseudophakic bullous keratopathy (one case), leukoma adherence (one case), herpetic keratitis (one case), and recurrent erosion syndrome (one case)
¶P. aeruginosa group included cataract surgery (four cases) and pars plana vitrectomy due to proliferative diabetic retinopathy (one case); P. putida group included cataract surgery (two cases) and Ahmed valve implantation due to neovascular glaucoma (one case)
**P. aeruginosa group included hypertension only (four cases), diabetes mellitus (three cases), cardiovascular abnormality with hypertension (two cases), and cardiovascular abnormality only (one case). P. putida group included hypertension only (three cases), diabetes mellitus with hypertension (one case), hepatitis B with hypertension (one case), rheumatoid arthritis (one case), and atrial septal defect (one case)
Clinical characteristics and treatment outcomes of Pseudomonas aeruginosa and P. putida keratitis
| Characteristics |
|
| |
|---|---|---|---|
| Central lesion‡ | 24 (72.7) | 12 (75.0) | 1.000* |
| Epithelial defect size ≥5 mm2 | 21 (63.6) | 9 (56.3) | 0.619 |
| Hypopyon | 15 (45.5) | 1 (6.3) | 0.006 |
| Epithelial healing time ≥ 10 days | 20 (60.6) | 9 (56.3) | 0.771 |
| Complications** | 5 (15.2) | 3 (18.8) | 1.000* |
| Surgical treatment++ | 5 (15.2) | 2 (12.5) | 1.000* |
| Presenting BCVA§ | |||
| mean ± SD, logMAR | 1.66 ± 0.95 | 1.53 ± 1.10 | 0.675† |
| < 0.1, Snellen | 20 (62.5) | 9 (56.3) | 0.676 |
| Final BCVA§ | |||
| mean ± SD, logMAR | 0.98 ± 1.12 | 1.09 ± 1.22 | 0.760† |
| < 0.1, Snellen | 9 (28.1) | 6 (37.5) | 0.509 |
| Decreased BCVA#§ | 8 (25.0) | 5 (31.3) | 0.735* |
| Clinical outcome§¶ | |||
| Good | 11 (34.4) | 7 (43.8) | 0.527 |
| Moderate | 11 (34.4) | 3 (18.8) | 0.328* |
| Poor | 10 (31.2) | 6 (37.5) | 0.665 |
BCVA best corrected visual acuity, logMAR logarithm of the minimum angle of resolution, SD standard deviation
Values indicate numbers (proportion) unless otherwise noted
*The p-value was calculated using Fisher’s exact test
†The p-value was calculated using independent t-test
‡Corneal lesion is located within the 1/2 radius from the center of the cornea
**Complicated cases in P. aeruginosa group were persistent epithelial defect (two cases), impending corneal perforation (two cases), and progression of infection (one case); those in P. putida group was persistent epithelial defect (three cases)
++Surgical treatment cases in P. aeruginosa group were amniotic membrane transplantation (three cases), tarsorrhaphy (one case), and evisceration (one case); those in P. putida group was amniotic membrane transplantation (two cases)
§Total n = 48: One young child in the P. aeruginosa group who could not read letters was excluded
#Cases of final BCVA worsened from presentation
¶The clinical outcomes were assessed at the end of three months or at the completion of treatment and classified into three groups, as defined by Green [11].
Antibiotics susceptibility of Pseudomonas aeruginosa and P. putida keratitis during the 1998–2017 period
| Antibiotics |
|
| |
|---|---|---|---|
| Beta-lactams | |||
| Ticarcillin | 17/20 (85.0) | 0/7 (0.0) | < 0.001* |
| Tic/clav | 20/27 (74.1) | 0/16 (0.0) | < 0.001 |
| Piperacillin | 28/29 (96.6) | 12/16 (75.0) | 0.047* |
| Pip/tazo | 18/19 (94.7) | 12/16 (75.0) | 0.156* |
| Carbenicillin | 10/14 (71.4) | – | – |
| Amp/sul | 0/17 (0.0) | 0/12 (0.0) | – |
| Cefotaxime | 0/28 (0.0) | 1/16 (6.3) | 0.364* |
| Ceftazidime | 31/33 (93.9) | 14/16 (87.5) | 0.588* |
| Cefepime | 30/31 (96.8) | 15/16 (93.8) | 1.000* |
| Aztreonam | 16/29 (55.2) | 1/16 (6.3) | 0.001 |
| Imipenem | 33/33 (100.0) | 13/16 (81.3) | 0.030* |
| Meropenem | 28/28 (100.0) | 14/16 (87.5) | 0.127* |
| Aminoglycosides | |||
| Amikacin | 30/33 (90.9) | 16/16 (100.0) | 0.541* |
| Gentamicin | 30/33 (90.9) | 15/16 (93.8) | 1.000* |
| Tobramycin | 14/15 (93.3) | 7/7 (100.0) | 1.000* |
| Netilmicin | 2/2 (100.0) | 3/4 (75.0) | 1.000* |
| Isepamicin | 2/2 (100.0) | 3/4 (75.0) | 1.000* |
| Fluoroquinolones | |||
| Ciprofloxacin | 28/29 (96.6) | 14/16 (87.5) | 0.285* |
| Levofloxacin | 6/7 (85.7) | 6/7 (85.7) | 1.000* |
| Others | |||
| Pipemidic acid | 3/4 (75.0) | – | – |
| Tigecycline | 2/16 (12.5) | 1/9 (11.1) | 1.000* |
| TMP/SMX | 0/28 (0.0) | 0/16 (0.0) | – |
| Colistin | 18/18 (100.0) | 15/15 (100.0) | – |
Tic/clav = ticarcillin/clavulanate; Pip/tazo = piperacillin/tazobactam; Amp/sul = ampicillin/sulbactam;
TMP/SMX = trimethoprim/sulfamethoxazole
Values are presented as n1/n2 (%), where n1 is the number of isolates with susceptibility and n2 is the number of tested isolates
*The p-value was calculated using Fisher’s exact test
Risk factors for poor clinical outcome* in Pseudomonas keratitis† (univariate and multivariate logistic regression analysis‡)
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Hypopyon | 3.57 | 0.98–12.97 | 0.053 | 9.02 | 1.33–61.25 | 0.024 |
| Epithelial healing time ≥ 10 (days) | 4.91 | 1.17–20.62 | 0.030 | – | – | – |
| Age ≥ 50 (years) | 5.57 | 1.33–23.44 | 0.019 | 4.85 | 0.74–31.68 | 0.099 |
| Nonuse of CLs | 7.86 | 0.91–67.57 | 0.060 | – | – | – |
| Previous ocular surgery | 9.00 | 1.56–51.95 | 0.014 | 6.48 | 0.72–58.65 | 0.097 |
| Previous OSD | 16.11 | 3.38–76.76 | < 0.001 | 10.79 | 1.67–69.76 | 0.012 |
CI confidence interval, CL contact lens, OSD ocular surface disease, OR odds ratio
*The clinical outcomes were assessed at the end of three months or at the completion of treatment and classified into three groups, as defined by Green [11].
†Total cohort of P. aeruginosa and P. putida keratitis, total n = 48: One young child in the P. aeruginosa group who could not read letters was excluded
‡Multivariate logistic regression analysis was performed using the backward-conditional method for the factors with a p-value < 0.1 in univariate logistic regression analysis